Ofatumumab studie 61:
-
Ofatumumab studie 61:
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
This study is not yet open for participant recruitment.
Verified on July 2011 by OHSU Knight Cancer InstituteFirst Received on July 13, 2011. Last Updated on July 18, 2011 History of Changes
Sponsor: OHSU Knight Cancer Institute
Collaborator: National Cancer Institute (NCI)Information provided by: OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT01397591
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind